Ua. Vitt et al., In vivo treatment with GDF-9 stimulates primordial and primary follicle progression and theca cell marker CYP17 in ovaries of immature rats, ENDOCRINOL, 141(10), 2000, pp. 3814-3820
Growth differentiation factor (GDF)-9 is a cystine knot-containing hormone
of the transforming growth factor-beta superfamily produced by the oocyte.
In GDF-9 null mice, follicle development is arrested at the primary stage a
nd GDF-9 treatment in vitro enhances preantral follicle growth. Immature fe
male rats were treated with recombinant GDF-9 for 7 or 10 days. At 10 days,
treatment with GDF-9 augmented ovarian weights, concomitant with an increa
se in the number of primary and small preantral follicles by 30 and 60%, re
spectively. Furthermore, the number of primordial follicles was decreased b
y 29%, but the number of large preantral follicles was not affected. In con
trast, treatment with FSH increased the number of small and large preantral
follicles by 36 and 177% but did not influence the number of primary and p
rimordial follicles. Immunoblot analysis showed an increase of CYP17, a the
ca cell marker, in the ovarian homogenate after treatment with GDF-9 but no
t FSH. The present results indicate that in vivo treatment with GDF-9 enhan
ces the progression of primordial and primacy follicles into small preantra
l follicles. Thus, GDF-9 treatment could provide an alternative approach to
stimulate early follicle development in addition to the widely used FSH th
at acts mainly on the development of more advanced follicles.